Acc2014 7
-
Upload
astrazenecaoz -
Category
Health & Medicine
-
view
26 -
download
0
description
Transcript of Acc2014 7
![Page 1: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/1.jpg)
Date of preparation April 2014 │BRI001081
ACC.14Annual Scientific Sessions of the American College of Cardiology
Washington DC
29-31 March 2014
![Page 2: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/2.jpg)
Date of preparation April 2014 │BRI001081
Disclaimer
• AstraZeneca abides by the Medicines Australia Code of Conduct (Edition 17) and AstraZeneca Global Policies, and as such will not engage in the promotion of unregistered products or unapproved indications.
• These highlights have been suggested by a group of cardiologists who attended ACC.14, compiled by an external medical writer and sponsored by AstraZeneca.
• Statements of fact and opinions expressed are those of the speakers individually and, unless expressly stated to the contrary, are not the opinion or position of AstraZeneca. AstraZeneca does not endorse or approve, and assumes no responsibility for, the content, accuracy, or completeness of the information presented. Presentations are intended for educational purposes only and do not replace independent professional judgement.
• Please refer to the appropriate approved Product Information before prescribing any agents mentioned in these highlights.
![Page 3: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/3.jpg)
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
CHOICE study: Self-expandable vs balloon-expandable prostheses for TAVR
Commentary:
Associate Professor John AthertonRoyal Brisbane and Women’s Hospital
Late-breaking trial
![Page 4: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/4.jpg)
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
![Page 5: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/5.jpg)
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Published online in JAMA
![Page 6: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/6.jpg)
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
![Page 7: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/7.jpg)
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
![Page 8: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/8.jpg)
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
![Page 9: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/9.jpg)
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
![Page 10: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/10.jpg)
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
![Page 11: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/11.jpg)
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
![Page 12: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/12.jpg)
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
![Page 13: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/13.jpg)
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
![Page 14: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/14.jpg)
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
![Page 15: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/15.jpg)
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
![Page 16: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/16.jpg)
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
![Page 17: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/17.jpg)
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
![Page 18: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/18.jpg)
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
![Page 19: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/19.jpg)
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
![Page 20: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/20.jpg)
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
![Page 21: Acc2014 7](https://reader036.fdocuments.us/reader036/viewer/2022070319/5583cf2ad8b42a61638b4d3e/html5/thumbnails/21.jpg)
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
• Balloon-expandable TAVR was superior to self-expanding TAVR based on a composite clinical endpoint largely driven by a reduced rate of incorrect positioning requiring more than one valve and a reduction in the rate of moderate/ severe prosthetic regurgitation.
• There was a lower permanent pacemaker requirement following balloon-expandable TAVI.
• Aortic valve regurgitation is a valid outcome measure in TAVR trials, but the clinical significance of regurgitation can vary markedly between patients.
• One size does not fit all. Further evaluation of both approaches should continue.
Commentary: Associate Professor John Atherton